期刊文献+

原发免疫性血小板减少症并发围术期深静脉血栓1例并文献复习及思考

Primary immune thrombocytopenia complicated with perioperative deep venous thrombosis:a case report and literature review
下载PDF
导出
摘要 目的探讨围术期合并原发免疫性血小板减少症(ITP)病例预防出血及血栓形成的临床应对方案。方法回顾性分析1例ITP患者并发围术期深静脉血栓的临床资料,并汇总复习相关文献资料。结果ITP患者不仅需关注血小板减少相关出血风险,也应当关注发生血栓事件风险。手术及升血小板治疗均有可能是ITP患者血栓发生的危险因素。围术期建议常规监测血常规、凝血功能及血管超声检查,适时停用升血小板药物,必要时需抗凝治疗,以预防及早期发现深静脉血栓。结论围术期的ITP患者需警惕血栓发生风险。 Objective To explore the clinical scheme in prevention of bleeding and thrombosis in perioperative patients with primary immune thrombocytopenia(ITP).Methods The clinical data of a patient with ITP and deep venous thrombosis during perioperative period were analyzed retrospectively,and the relevant literatures were summarized and reviewed.Results ITP patients should pay attention not only to the risk of thrombocytopenia related bleeding,but also to the risk of thrombotic events.Surgery and platelet raising therapy may be the risk factors of thrombosis in patients with ITP.During the perioperative period,it is recommended to routinely monitor blood routine,coagulation function,and vascular ultrasound,stop platelet raising drugs in time,and take anticoagulant treatment if it is necessary,so as to prevent and early detect deep venous thrombosis.Conclusion Patients with ITP should be alert to the risk of thrombosis during perioperative period.
作者 常婧 孙爱春 Chang Jing;Sun Aichun(Department of Gynecology,Weihai Central Hospital Affiliated to Qingdao University,Weihai 264400,China)
出处 《国际医药卫生导报》 2022年第11期1592-1594,共3页 International Medicine and Health Guidance News
关键词 原发免疫性血小板减少症 血栓 围术期 Primary immune thrombocytopenia Thrombosis Perioperative Period
  • 相关文献

参考文献6

二级参考文献48

  • 1华东FLAG方案治疗协作组,李军民,沈志祥.氟达拉滨联合阿糖胞苷和粒细胞集落刺激因子治疗复发和难治性急性髓系白血病[J].中华血液学杂志,2005,26(11):684-685. 被引量:17
  • 2Szer J.The prevalent predicament of relapsed acute myeloid leukemia[J].Hematology Am Soc Hematol Educ Program,2012,2012:43-48.
  • 3Chowdhury S,Seropian S,Marks PW.Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia[J].Am J Hematol,2009,84(9):599-600.
  • 4Song LX,Xu L,Li X,et al.Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia[J].Ann Hematol,2012,91(12):1879-1886.
  • 5Swerdlow SH,Campo E,Harris NL,et al.WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues[M].4ed.Lyon:International Agency for Research on Cancer,2008:130-139.
  • 6Kantarjian HM,Thomas XG,Dmoszynska A,et al.Multicenter,randomized,open-label,phase Ⅲ trial of decitabine versus patient choice,with physician advice,of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia[J].J Clin Oncol,2012,30(21):2670-2677.
  • 7Ferrara F.Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?[J].Hematol Oncol,2014,32(1):1-9.
  • 8C, eerts WH, Berqqvist D, Pineo GF, et al. Prevention of VenousThromboembolism:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (Sth Edition) [J ]. Chest, 2008,133 ( 6 Suppl ) : 381-453.
  • 9Hill J, Treasure T. Reducing the risk of venous thremboembolism (deep vein thrombosis and pulmonary embolism) in inpatients having surgery: summary of NICE guidance[J]. BMJ,2007, 334(7602) : 1053-1054.
  • 10Leizorovicz A. SMART Venography study steering committee. Epidemiology of post-operative venous thromboembolism inAsian patients. Results of the SMART venography study [ J ]. Haematologlca, 2007,92 (9) : 1194-1200.

共引文献515

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部